Muñoz-Hernández A M, Duquesroix B, Benítez-Del-Castillo J M
Fundación para la Investigación Biomédica, Instituto de Investigación Sanitaria, Hospital Clínico San Carlos (IdISSC), Madrid, España; Redes Temáticas de Investigación Cooperativa en la Red (RETICS), Instituto Carlos III, Madrid, España.
Nicox, Sophia-Antipolis, Francia.
Arch Soc Esp Oftalmol (Engl Ed). 2018 Mar;93(3):113-118. doi: 10.1016/j.oftal.2017.06.017. Epub 2017 Sep 8.
Non-interventional, observational, epidemiology study to assess clinical characteristics and frequency of adenovirus conjunctivitis diagnosed by AdenoPlus in patients who presented with signs and symptoms of acute conjunctivitis. Safety aspects during use of the test were analyzed as well.
This analysis presents the data obtained from the 386 patients enrolled in Spain. Patients had to present with acute signs and symptoms of conjunctivitis ≤7days. The minimum age was 1year old. Patients who had already used local antiviral therapies, topical steroids or immuno-modulators were not allowed to enter the study. A standardized questionnaire was used to collect patient's ocular history and test results.
A total of 386 patients were recruited in 22 sites, being analyzed 329 patients. Among them, the percentage of "AdenoPlus positive" was 36,2% (119/329). Before the test was performed, in 84,1% of the cases, investigators believed that the conjunctivitis was of viral origin but only 50,3% of the investigators had their clinical assessment confirmed by the test. Patients who tested positive for adenoviral conjunctivitis presented higher percentages of signs and symptoms than the rest of the patients.
None of the signs or symptoms could be qualified as pathognomonic of the disease, being difficult for the clinicians to perform an accurate diagnosis. AdenoPlus test is an antigen based immunoassay test that detects the presence of adenovirus directly from tears, and it can be an useful tool to help early differential diagnosis in patients with conjunctivitis signs and symptoms lasting for less than or equal to 7days.
进行非干预性、观察性流行病学研究，以评估出现急性结膜炎体征和症状的患者中，由AdenoPlus诊断出的腺病毒结膜炎的临床特征和发病率。同时分析该检测使用过程中的安全性。
本分析呈现了从西班牙入组的386例患者获得的数据。患者必须出现结膜炎急性体征和症状且病程≤7天。最小年龄为1岁。已使用局部抗病毒疗法、局部类固醇或免疫调节剂的患者不得进入该研究。使用标准化问卷收集患者的眼部病史和检测结果。
在22个地点共招募了386例患者，对329例患者进行了分析。其中，“AdenoPlus阳性”的比例为36.2%（119/329）。在进行检测前，84.1%的病例中，研究者认为结膜炎为病毒源性，但只有50.3%的研究者的临床评估被检测结果证实。腺病毒结膜炎检测呈阳性的患者出现体征和症状的比例高于其他患者。
没有任何体征或症状可被认定为该病的特征性表现，临床医生难以进行准确诊断。AdenoPlus检测是一种基于抗原的免疫分析检测，可直接从泪液中检测腺病毒的存在，对于持续时间小于或等于7天的结膜炎体征和症状患者，它可能是有助于早期鉴别诊断的有用工具。
